文献速递生殖医学妇科

良性卵巢肿瘤女性卵母细胞累积保存的结局与接受率

Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts.
PubMed 文献 · Reprod Biomed Online · 2021-05-13

法国里尔大学医院2016年1月至2019年12月的回顾性队列研究,分析70名平均27.9±4.8岁良性卵巢肿瘤女性的113个生育力保存周期。每周期获卵6.4±3.4枚、玻璃化冻存MII卵4.3±3.4枚,累积后每例冻存7.0±5.23枚MII卵;子宫内膜瘤组与其他囊肿组卵巢反应无差异,无严重不良事件。

要点

  • 良性卵巢肿瘤年轻女性应系统提供卵母细胞累积保存,似耐受良好
  • 每周期玻璃化冻存MII卵4.3±3.4枚,累积后每例7.0±5.23枚
  • 子宫内膜瘤与其他囊肿组的卵巢反应及卵母细胞队列无差异

核心结论

  • 卵母细胞累积保存应系统提供给良性卵巢肿瘤年轻女性,不受组织学类型限制,且似耐受良好。
  • 长期随访仍需评估卵母细胞累积对后续妊娠机会优化的有效性。

研究设计与样本

  • 单中心回顾性队列研究,法国里尔大学医院学术辅助生殖与生育力保存中心,2016年1月至2019年12月。
  • 共分析70名女性的113个生育力保存周期,年龄27.9±4.8岁;分为子宫内膜瘤组与皮样、黏液性或浆液性囊肿组。

主要发现

  • 89%的女性在生育力保存前接受过卵巢手术。
  • 卵巢刺激前平均抗苗勒管激素水平为12.5±8.7 pmol/l。
  • 每周期获卵6.4±3.4枚,玻璃化冻存MII卵4.3±3.4枚。
  • 全部患者同意卵母细胞累积方案并至少完成一个周期;36名(51%)患者完成两或三个生育力保存周期。
  • 累积后每例患者玻璃化冻存7.0±5.23枚MII卵;两组间卵巢反应与卵母细胞队列无差异。

临床怎么用

  • 对良性卵巢肿瘤年轻女性可系统提供卵母细胞累积保存,不受组织学类型限制。
  • 取卵后多数患者有腹胀、盆腔痛,无严重不良事件,方案似耐受良好。

局限性

  • 为回顾性单中心研究,长期随访尚未评估卵母细胞累积对后续妊娠的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What are ovarian stimulation cycle outcomes and acceptance rates of an oocyte accumulation programme in young women with benign ovarian tumour (BOT)? DESIGN: Retrospective cohort study conducted at the Academic Assisted Reproductive Technology and Fertility Preservation Centre, Lille University Hospital, between January 2016 and December 2019. The number of metaphase II oocytes per cycle and per patient after accumulation were evaluated. Two groups were identified for the analysis: endometrioma ('endometrioma') and dermoid, mucinous or serous cyst ('other cysts'). RESULTS: A total of 113 fertility-preservation cycles were analysed in 70 women aged 27.9 ± 4.8 years. Almost all women had undergone previous ovarian surgery before fertility preservation (89%). Mean anti-Müllerian hormone levels before ovarian stimulation was 12.5 ± 8.7 pmol/l. A total of 6.4 ± 3.4 oocytes were retrieved, and 4.3 ± 3.4 metaphase II (MII) oocytes were vitrified per cycle. All agreed to the oocyte accumulation programme and all underwent at least one cycle. To date, 36 (51%) patients achieved two or three fertility- preservation cycles. After accumulation, 7.0 ± 5.23 MII oocytes were vitrified per patient. No difference was found in ovarian response and oocyte cohort between the 'endometrioma' and 'other cysts' groups. Questionnaires completed after oocyte retrieval revealed abdominal bloating and pelvic pain in most patients, with no difference according to the type of cyst. No serious adverse events occurred. CONCLUSIONS: Oocyte accumulation should be systematically offered to young women with BOT irrespective of histological type, as it seems to be well-tolerated. Long-term follow-up is needed to assess the efficiency of oocyte accumulation to optimize the chances of subsequent pregnancies.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Legrand C, Keller L, Collinet P, et al. Oocyte accumulation for fertility preservation in women with benign ovarian tumours with a history of previous surgery, multiple or large cysts. Reprod Biomed Online. 2021. PMID: 34247989. doi:10.1016/j.rbmo.2021.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。